Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phentermine SCHEMBL5708330 | 0.92 | SLC6A2 (0.61) | LOXL2ALDH1A1SLC6A2HTR2ASLC6A4 | |
| Sulfuric Acid SCHEMBL2003766 | 0.92 | LOXL2 (0.49) | LOXL2ALDH1A1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL75530 | 0.84 | LOXL2 (0.55) | LOXL2ALDH1A1IDO1TSHRACHE | |
| SCHEMBL9307922 | 0.81 | LOXL2 (0.58) | LOXL2ALDH1A1IDO1TSHRACHE | |
| SCHEMBL21058259 | 0.81 | TSHR (0.55) | LOXL2ALDH1A1IDO1TSHRACHE | |
| SCHEMBL9053221 | 0.81 | LOXL2 (0.57) | LOXL2ALDH1A1IDO1TSHRCYP2C19 | |
| SCHEMBL7107843 | 0.81 | LOXL2 (0.52) | LOXL2ALDH1A1IDO1TSHRACHE | |
| SCHEMBL97944 | 0.81 | LOXL2 (0.52) | LOXL2ALDH1A1IDO1TSHRACHE | |
| SCHEMBL1627332 | 0.81 | TSHR (0.53) | LOXL2ALDH1A1IDO1TSHRACHE | |
| SCHEMBL7107845 | 0.79 | LOXL2 (0.50) | LOXL2ALDH1A1IDO1TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
| US-20120071654-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7994165-B2 | Aryl aniline derivatives as β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1706371-B1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2011-04-06 | — | — | EP | disclosed |
| CN-1910137-B | As beta2Arylaniline derivatives of adrenergic receptor agonists | THERAVANCE INC | 2010-05-26 | — | — | CN | disclosed |
| US-20100087410-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7622467-B2 | 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one; extended duration of action; potency, selectivity; asthma, chronic obstructive pulmonary disease, antiinflammatory, pre-term labor, neurological and cardiac disorders | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| CN-1910137-A | As beta2Arylaniline derivatives of adrenergic receptor agonists | THERAVANCE INC (US) | 2007-02-07 | — | — | CN | disclosed |
| US-6939867-B2 | Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents | PFIZER INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050159448-A1 | Aryl aniline derivatives as beta2 adrenergic receptor agonists | THERAVANCE, INC. | 2005-07-21 | — | — | US | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020128247-A1 | Beta3 agonists and uses thereof | DOW ROBERT L (US) | 2002-09-12 | — | — | US | disclosed |
| EP-1236723-A1 | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-4894219-A | ADRENERGIC BLOCKING AGENTS, ANALYZING | UNIVERSITY OF FLORIDA (US) | 1990-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071654-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | LOXL2 1113/4885ALDH1A1 532/4885SLC6A2 119/4885 |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | LOXL2 2462/4885ALDH1A1 3527/4885SLC6A2 1814/4885 |
| US-20020128247-A1 | Beta3 agonists and uses thereof | ADRB3, ADRB1, ADRB2 | LOXL2 1641/4885ALDH1A1 764/4885SLC6A2 161/4885 |
| US-20050159448-A1 | Aryl aniline derivatives as beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | LOXL2 1113/4885ALDH1A1 532/4885SLC6A2 119/4885 |
| US-20100087410-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | LOXL2 1113/4885ALDH1A1 532/4885SLC6A2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.